GPC Biotech receives Orphan Medicinal Product Designation.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001709:Biotechnology; D054713:Bryostatins; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015195:Drug Design; D004938:Esophageal Neoplasms / Q000188:drug therapy*; D005062:European Union; D006801:Humans; D007783:Lactones / Q000008:administration & dosage; D018942:Macrolides; D017239:Paclitaxel / Q000008:administration & dosage; D014481:United States
D054713:Bryostatins; D007783:Lactones; D018942:Macrolides; C046785:bryostatin 1; D017239:Paclitaxel